WO1998052603A3 - An influenza enveloped dna vaccine - Google Patents

An influenza enveloped dna vaccine Download PDF

Info

Publication number
WO1998052603A3
WO1998052603A3 PCT/EP1998/003050 EP9803050W WO9852603A3 WO 1998052603 A3 WO1998052603 A3 WO 1998052603A3 EP 9803050 W EP9803050 W EP 9803050W WO 9852603 A3 WO9852603 A3 WO 9852603A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
mumps virus
virosomes
virus
biologically active
Prior art date
Application number
PCT/EP1998/003050
Other languages
French (fr)
Other versions
WO1998052603A2 (en
Inventor
Maria Grazia Cusi
Reinhard Glueck
Ernst WAELTI
Original Assignee
Schweiz Serum & Impfinst
Maria Grazia Cusi
Reinhard Glueck
Ernst WAELTI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst, Maria Grazia Cusi, Reinhard Glueck, Ernst WAELTI filed Critical Schweiz Serum & Impfinst
Priority to AU79153/98A priority Critical patent/AU7915398A/en
Priority to EP98929369A priority patent/EP0988052A2/en
Publication of WO1998052603A2 publication Critical patent/WO1998052603A2/en
Publication of WO1998052603A3 publication Critical patent/WO1998052603A3/en
Priority to US10/269,501 priority patent/US20030113347A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Described are virosomes comprising cationic lipids, biologically active influenza hemagglutinin protein or biologically active derivatives thereof and nucleic acids encoding antigens from pathogenic sources in their insides, preferably antigens from mumps virus wherein said antigens are derived from conserved external and internal proteins of said virus. Provided are virosomes which may advantageously be formulated as vaccines capable of inducing strong neutralizing antibody and cytotoxic T cell responses as well as protection to pathogenic sources such as a mumps virus. Furthermore, vaccines comprising recombinant DNA derived from DNA encoding conserved external and internal proteins from mumps virus are described.
PCT/EP1998/003050 1991-05-08 1998-05-22 An influenza enveloped dna vaccine WO1998052603A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU79153/98A AU7915398A (en) 1997-05-23 1998-05-22 An influenza enveloped dna vaccine
EP98929369A EP0988052A2 (en) 1997-05-23 1998-05-22 An influenza enveloped dna vaccine
US10/269,501 US20030113347A1 (en) 1991-05-08 2002-10-10 Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97108390.2 1997-05-23
EP97108390 1997-05-23

Publications (2)

Publication Number Publication Date
WO1998052603A2 WO1998052603A2 (en) 1998-11-26
WO1998052603A3 true WO1998052603A3 (en) 1999-05-14

Family

ID=8226824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003050 WO1998052603A2 (en) 1991-05-08 1998-05-22 An influenza enveloped dna vaccine

Country Status (3)

Country Link
EP (1) EP0988052A2 (en)
AU (1) AU7915398A (en)
WO (1) WO1998052603A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489019A1 (en) * 2001-06-15 2002-12-27 Nordic Vaccine Technology A/S Therapeutical vaccination
EA008497B1 (en) * 2002-11-21 2007-06-29 Певион Биотех Лтд. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US9603921B2 (en) 2004-10-27 2017-03-28 Janssen Vaccines Ag Virosome particles comprising antigens from influenza virus and hepatitis b virus
EP1676569A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
EP2471937A3 (en) * 2005-11-24 2013-04-24 The Research Foundation for Microbial Diseases of Osaka University Recombinant polyvalent vaccine
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305229A1 (en) * 1987-07-07 1989-03-01 Transgene S.A. Viral vector and recombinant DNA encoding one or more structural proteins (HA,F and/or NP) of a morbillivirus
WO1992019267A1 (en) * 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1994025600A1 (en) * 1993-04-30 1994-11-10 Smithkline Beecham Biologicals S.A. Recombinant antigens from mumps virus and their use in vaccines
WO1995010632A1 (en) * 1993-10-12 1995-04-20 Emory University Anti-paramyxovirus screening method and vaccine
US5550289A (en) * 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
WO1996040962A1 (en) * 1995-06-07 1996-12-19 Megabios Corporation Cationic lipid:dna complexes for gene targeting

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550289A (en) * 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
EP0305229A1 (en) * 1987-07-07 1989-03-01 Transgene S.A. Viral vector and recombinant DNA encoding one or more structural proteins (HA,F and/or NP) of a morbillivirus
WO1992019267A1 (en) * 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1994025600A1 (en) * 1993-04-30 1994-11-10 Smithkline Beecham Biologicals S.A. Recombinant antigens from mumps virus and their use in vaccines
WO1995010632A1 (en) * 1993-10-12 1995-04-20 Emory University Anti-paramyxovirus screening method and vaccine
WO1996040962A1 (en) * 1995-06-07 1996-12-19 Megabios Corporation Cationic lipid:dna complexes for gene targeting

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATO T ET AL: "SYNTHETIC CATIONIC AMPHIPHILE FOR LIPOSOME-MEDIATED DNA TRANSFECTION WITH LESS CYTOTOCICITY", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), vol. 19, no. 6, 1 June 1996 (1996-06-01), pages 860 - 863, XP000594656 *
STERNBERG B: "MORPHOLOGY OF CATIONIC LIPOSOME/DNA COMPLEXES IN RELATION TO THEIR CHEMICAL COMPOSITION", JOURNAL OF LIPOSOME RESEARCH, vol. 6, no. 3, August 1996 (1996-08-01), pages 515 - 533, XP002048618 *
WASAN E K ET AL: "PLASMID DNA IS PROTECTED AGAINST ULTRASONIC CAVITATION-INDUCED DAMAGE WHEN COMPLEXED TO CATIONIC LIPOSOMES", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, no. 4, 1 April 1996 (1996-04-01), pages 427 - 433, XP000558752 *
WILD ET AL.: "CONSTRUCTION OF VACCINIA VIRUS RECOMBINANTS EXPRESSING SEVERAL MEASLES VIRUS PROTEINS AND ANALYSIS OF THEIR EFFICACY IN VACCINATION OF MICE", JOURNAL OF GENERAL VIROLOGY, vol. 173, no. 2, February 1992 (1992-02-01), pages 359 - 367, XP002097543 *

Also Published As

Publication number Publication date
WO1998052603A2 (en) 1998-11-26
EP0988052A2 (en) 2000-03-29
AU7915398A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
WO2001060402A3 (en) Proteosome influenza vaccine
PT1090033E (en) HCV ENVELOPE PROTEIN PARTICLES: USED FOR VACCINATION
CO5070644A1 (en) VACCINES INCLUDING PROTEINS E6 of HPV AND / OR E7 of HPV TOGETHER WITH A CPG OLIGONUCLEOTIDE AS ASSISTANT
ES2129386T1 (en) INFLUENZA VACCINE.
CY1110585T1 (en) PACKAGING OF CpG IMMUNIATORS WITH PARTICULAR VIRUSES: METHOD OF PREPARATION AND USE
BR9406007A (en) DNA construction, polynucleotide vaccine, vector, processes to protect against human influenza virus infection, to use an influenza virus gene, to induce immune responses against infection or disease caused by influenza virus strains, composition of nucleic acid constructs and use of a human influenza virus gene
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
DE69632235D1 (en) Newcastle disease viral vaccines combined
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2004080403A3 (en) Influenza virus vaccine
WO2002009645A3 (en) Intercellular transport protein linked to an antigen as a molecular vaccine
ES2151506T3 (en) RECOMBINANT DNA MOLECULES THAT CODIFY AMYNOPEPTIDASE ENZYMES AND THEIR USE IN THE PREPARATION OF VACCINES AGAINST INFECTIONS BY HELMINS.
WO1998052603A3 (en) An influenza enveloped dna vaccine
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
FR2828405B1 (en) ANTI-CORONAVIRUS VACCINE
WO2002028998A3 (en) Chlamydia pmp proteins, gene sequences and uses thereof
KR900701291A (en) Vaccines and diagnostic tests for hemophilus influenza
DE60231821D1 (en) RECOMBINANT TOLLWOOD VACCINES AND METHOD FOR THEIR PREPARATION AND USE
WO2000047223A3 (en) Viral vaccine
DK1499349T3 (en) Recombinant Hybrid Allergen Hybrid Allergen Constructs That Maintain Immunogenic Allergy Immunogenicity
FI953371A (en) Improved vaccines for immunization against TBE virus infection and method for their preparation
WO2003022880A3 (en) Synthetic hcv envelope proteins and their use for vaccination
ZA941853B (en) Stimulation of immune response by viral protein
FR2724385B1 (en) FELINE INFECTIOUS PERITONITIS VACCINE.
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09264551

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998929369

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998549980

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998929369

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWR Wipo information: refused in national office

Ref document number: 1998929369

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998929369

Country of ref document: EP